Host genes associated with HIV/AIDS: advances in gene discovery

Trends in Genetics

Volumn 26, Issue 3, 2010, Pages 119-131

  An, Ping ^a   Winkler, Cheryl A ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE 9; CYCLOPHILIN A; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MRE11 PROTEIN; NUCLEOPORIN 98; PROTEIN KINASE B; RANTES; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TRIPARTITE MOTIF PROTEIN 5; VIF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOTOXIC T LYMPHOCYTE; DRUG HYPERSENSITIVITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; IMMUNOMODULATION; INFECTION SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HIV; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 76749167054     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2010.01.002     Document Type: Review

References (107)

1. O'Brien S.J., and Nelson G.W. Human genes that limit AIDS. Nature genetics 36 (2004) 565-574
2. Dean M., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996) 1856-1862
3. Hutter G., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 (2009) 692-698
4. Shacklett B.L. Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. Current HIV/AIDS reports 3 (2006) 26-31
5. Walker B.D. Elite control of HIV Infection: implications for vaccines and treatment. Top. HIV Med. 15 (2007) 134-136
6. Miura T., et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82 (2008) 8422-8430
7. Carrington M., et al. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16 (2008) 620-627
8. Carrington M., and O'Brien S.J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54 (2003) 535-551
9. Carrington M., et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 (1999) 1748-1752
10. Gao X., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344 (2001) 1668-1675
11. Thobakgale C.F., et al. Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. J. Virol. 83 (2009) 10234-10244
12. Mackelprang R.D., et al. Maternal HLA homozygosity and mother-child HLA concordance increase the risk of vertical transmission of HIV-1. J. Infect. Dis. 197 (2008) 1156-1161
13. Boutwell C.L., et al. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J. Virol. 83 (2009) 2460-2468
14. Colombo S., et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198 (2008) 864-867
15. Hyrcza M.D., et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J. Virol. 81 (2007) 3477-3486
16. Ball T.B., et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 21 (2007) 1091-1101
17. Vasilescu A., et al. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3354-3359
18. Ioannidis J.P., et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann. Intern. Med. 135 (2001) 782-795
19. Hendrickson S.L., et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J. Acquir. Immune Defic. Syndr. 48 (2008) 263-271
20. McDermott D.H., et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352 (1998) 866-870
21. Martin M.P., et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282 (1998) 1907-1911
22. An P., et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 14 (2000) 2117-2122
23. He W., et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4 (2008) 52-62
24. Horne K.C., et al. Duffy antigen polymorphisms do not alter progression of HIV in African Americans in the MACS cohort. Cell Host Microbe 5 (2009) 415-417
25. Julg B., et al. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. Cell Host Microbe 5 (2009) 413-415
26. Walley N.M., et al. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe 5 (2009) 408-410
27. Winkler C.A., et al. Expression of Duffy antigen receptor for chemokines (DARC) has no effect on HIV-1 acquisition or progression to AIDS in African Americans. Cell Host Microbe 5 (2009) 411-413
28. An P., et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10002-10007
29. Liu H., et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4581-4585
30. Duggal P., et al. The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users. J. Acquir. Immune Defic. Syndr. 38 (2005) 584-589
31. Ahlenstiel G., et al. Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection - a prospective cross-sectional study. World J. Gastroenterol. 11 (2005) 7631-7638
32. Wichukchinda N., et al. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS 20 (2006) 189-196
33. Liu X.L., et al. [Preliminary study on the association of chemokine RANTES gene polymorphisms with HIV-1 infection in Chinese Han population]. Zhonghua Liu Xing Bing Xue Za Zhi 24 (2003) 971-975
34. Rathore A., et al. Association of RANTES -403 G/A, -28 C/G and In1.1 T/C polymorphism with HIV-1 transmission and progression among North Indians. J. Med. Virol. 80 (2008) 1133-1141
35. Koizumi Y., et al. RANTES -28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs. AIDS Res. Hum. Retroviruses 23 (2007) 713-719
36. Iqbal S.M., et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J. Infect. Dis. 192 (2005) 728-738
37. Gonzalez E., et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307 (2005) 1434-1440
38. Urban T.J., et al. CCL3L1 and HIV/AIDS susceptibility. Nat. Med. 15 (2009) 1110-1112
39. Field S.F., et al. Experimental aspects of copy number variant assays at CCL3L1. Nat. Med. 15 (2009) 1115-1117
40. Bhattacharya T., et al. Reply to: "CCL3L1 and HIV/AIDS susceptibility". Nat. Med. 15 (2009) 1112-1115
41. Chiu Y.L., and Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26 (2008) 317-353
42. Yu X., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
43. Valcke H.S., et al. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 20 (2006) 1984-1986
44. An P., et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 78 (2004) 11070-11076
45. Do H., et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J. Infect. Dis. 191 (2005) 159-163
46. Reddy K., et al. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24 (2010) 195-204
47. Biasin M., et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J. Infect. Dis. 195 (2007) 960-964
48. Jin X., et al. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 4 (2007) 20
49. Pace C., et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80 (2006) 9259-9269
50. Jin X., et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79 (2005) 11513-11516
51. Kidd J.M., et al. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3 (2007) e63
52. An P., et al. APOBEC3B deletion and risk of HIV-1 acquisition. J. Infect. Dis. 200 (2009) 1054-1058
53. An P., et al. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 3 (2007) e19
54. Stremlau M., et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 (2004) 848-853
55. Sokolskaja E., and Luban J. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr. Opin. Microbiol. 9 (2006) 404-408
56. Javanbakht H., et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 354 (2006) 15-27
57. Nakajima T., et al. Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection. AIDS 23 (2009) 2091-2100
58. Sawyer S.L., et al. High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr. Biol. 16 (2006) 95-100
59. Goldschmidt V., et al. Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 3 (2006) 54
60. van Manen D., et al. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 4 (2008) e18
61. Speelmon E.C., et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J. Virol. 80 (2006) 2463-2471
62. Kaumanns P., et al. Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants. Retrovirology 3 (2006) 79
63. Sewram S., et al. Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. J. Infect. Dis. 199 (2009) 1657-1663
64. An P., et al. Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog. 3 (2007) e88
65. Bleiber G., et al. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J. Virol. 79 (2005) 12674-12680
66. Rits M.A., et al. Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection. PloS One 3 (2008) e3975
67. Li J., et al. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorg. Med. Chem. 17 (2009) 3177-3188
68. Limou S., et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J. Infect. Dis. 199 (2009) 419-426
69. Le Clerc S., et al. Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J. Infect. Dis. 200 (2009) 1194-1201
70. Dalmasso C., et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PloS One 3 (2008) e3907
71. Fellay J., et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317 (2007) 944-947
72. Herbeck J.T., et al. Multi-stage genome-wide association study of HIV-1 disease progression to clinical. AIDS J. Infect. Dis. 201 (2010) 618-626
73. Kopp J.B., and Winkler C. HIV-associated nephropathy in African Americans. Kidney Int. Suppl. 63 Suppl 83 (2003) S43-49
74. Kopp J.B., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 40 (2008) 1175-1184
75. Brass A.L., et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 (2008) 921-926
76. Yeung M.L., et al. A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J. Biol. Chem. 284 (2009) 19463-19473
77. Konig R., et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135 (2008) 49-60
78. Zhou H., et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4 (2008) 495-504
79. Nguyen D.G., et al. Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening. Virology 362 (2007) 16-25
80. Imbeault M., et al. Microarray study reveals that HIV-1 induces rapid type-I interferon-dependent p53 mRNA up-regulation in human primary CD4+ T cells. Retrovirology 6 (2009) 5
81. Chan E.Y., et al. Dynamic host energetics and cytoskeletal proteomes in human immunodeficiency virus type 1-infected human primary CD4 cells: analysis by multiplexed label-free mass spectrometry. J. Virol. 83 (2009) 9283-9295
82. Nathans R., et al. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol. Cell 34 (2009) 696-709
83. Goldstein D.B. Common genetic variation and human traits. N. Engl. J. Med. 360 (2009) 1696-1698
84. Fauci A.S., et al. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124 (1996) 654-663
85. Bushman F.D., et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 5 (2009) e1000437
86. Bashirova A.A., et al. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J. Virol. 80 (2006) 6757-6763
87. Catano G., et al. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PloS One 3 (2008) e3636
88. Deeks S.G., and Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 (2007) 406-416
89. Loeuillet C., et al. In vitro whole-genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol. 6 (2008) e32
90. van Manen D., et al. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 23 (2009) 19-28
91. Lewden, C. et al. (2009) Comparison of early CD4 T-cell count in HIV-1 seroconverters in Cote d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts. J. Acquir. Immune Defic. Syndr. [Epub ahead of print] PMID: 19745754
92. Oh D.Y., et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PloS One 3 (2008) e2747
93. van Loggerenberg F., et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PloS One 3 (2008) e1954
94. Land A.M., et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82 (2008) 8172-8182
95. Tang J., et al. Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples. J. Immunol. 181 (2008) 2626-2635
96. Singh K.K., et al. Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. J. Acquir. Immune Defic. Syndr. 49 (2008) 259-265
97. Smith M.W., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277 (1997) 959-965
98. Duggal P., et al. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun. 4 (2003) 245-250
99. Garcia-Moruja C., et al. Molecular phenotype of CXCL12beta 3'UTR G801A polymorphism (rs1801157) associated to HIV-1 disease progression. Curr. HIV Res. 7 (2009) 384-389
100. Winkler C., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279 (1998) 389-393
101. He W., et al. Reply to: "Experimental aspects of copy number variant assays at CCL3L1". Nat. Med. 15 (2009) 1117-1120
102. Martin M.P., et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J. Virol. 78 (2004) 14053-14056
103. Shin H.D., et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14467-14472
104. An P., et al. A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals. J. Infect. Dis. 188 (2003) 228-231
105. Kanari Y., et al. Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS 19 (2005) 1015-1024
106. Koning F.A., et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83 (2009) 9474-9485
107. Harari A., et al. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83 (2009) 295-303